Chronic Myeloid Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Myeloid Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-03-10Clinical Trial Update: An Exploratory Study of High-dose Glivec in Patients With CML-CP Using Molecular Endpoints [Phase 2]
Phase 2 exploratory trial evaluating high-dose Glivec (imatinib) in chronic myeloid leukemia in chronic phase using molecular endpoints; stu…
-
CLINICAL_TRIALS trial_result · 2021-02-03Clinical Trial Update: Cardiovascular Assessment of Ponatinib as Third Line Treatment in Chronic Phase Chronic Myeloid Leukemia [Phase 2]
Phase 2 clinical trial updating cardiovascular assessment of ponatinib as a third-line treatment in chronic myeloid leukemia.
-
CLINICAL_TRIALS trial_result · 2021-01-14Clinical Trial Update: Nilotinib Treatment-free Remission Study in CML (Chronic Myeloid Leukemia) Patients [Phase 2]
Phase 2 study evaluating nilotinib treatment-free remission in chronic myeloid leukemia patients has completed, with results posted January …
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop) [Phase 2]
The ENESTop Phase 2 trial reports treatment-free remission after achieving sustained deep molecular response (MR4.5) in chronic myeloid leuk…
-
CLINICAL_TRIALS trial_result · 2021-01-13Clinical Trial Update: Nilotinib 300 mg BID in Newly Diagnosed CP-CML Patients to Verify Disappearance of CD34+/Lin-Ph+ Cells [Phase 2]
Phase 2 trial evaluating nilotinib 300 mg twice daily in newly diagnosed chronic-phase CML to verify disappearance of CD34+/Lin-Ph+ cells.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2021-01-07Clinical Trial Update: Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML) [Phase 2]
Phase 2 trial evaluating azacitidine after allogeneic stem cell transplantation for chronic myeloid leukemia has been completed with posted …
-
CLINICAL_TRIALS trial_result · 2020-12-31Clinical Trial Update: Phase III Trial Evaluating the Effectiveness of a Dose Adjustment of Imatinib Mesylate on the Molecular Response [Phase 3]
Phase III trial assessing a dose adjustment of imatinib mesylate for molecular response in chronic-phase myeloid leukemia; study terminated …
-
FDA approval · 2020-12-08FDA Approved: TASIGNA — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for Tasigna (nilotinib) submitted by Novartis Pharmaceuticals Corporation. This action pertains to a…
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Clofarabine Combinations in Relapsed/Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) and Myeloid Blast Phase Chronic Myeloid Leukemia (CML) [Phase 2]
Phase 2 trial update of clo farabine combinations in relapsed/refractory AML and MDS (and myeloid blast phase CML) with results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-08Clinical Trial Update: Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study) [Phase 1, Phase 2]
Extension study evaluating nilotinib in adults with imatinib-resistant/intolerant CML or relapse/refractory Philadelphia-positive ALL; compl…
-
CLINICAL_TRIALS trial_result · 2020-11-24Clinical Trial Update: Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia [Phase 2]
Phase 2 trial updates bosutinib in Japanese adults with newly diagnosed chronic phase chronic myeloid leukemia; results posted after complet…
-
CLINICAL_TRIALS trial_result · 2020-11-05Clinical Trial Update: Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy [Phase 2]
Phase 2 trial evaluating allogeneic stem cell transplantation for chronic myeloid leukemia patients failing TKI therapy has completed.
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia [Phase 1, Phase 2]
Phase I/II study evaluating nilotinib combined with ruxolitinib in TKI-resistant Philadelphia chromosome-positive leukemias; trial status co…
-
CLINICAL_TRIALS trial_result · 2020-10-22Clinical Trial Update: An Open-Label, Phase I/II Study of Two Different Schedules of Dasatinib (Sprycel) and Decitabine (Dacogen) Used in Combination for Patients With Accelerated or Blastic Phase Chronic Myelogenous Leukemia (Protocol CA180357) [Phase 1, Phase 2]
Open-label Phase I/II study evaluating two schedules of dasatinib plus decitabine in accelerated or blastic phase chronic myeloid leukemia; …
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib) [Phase 2]
Phase 2 clinical trial evaluating reduction and discontinuation strategies for TKIs imatinib, nilotinib, dasatinib, and bosutinib in BCR-ABL…
-
CLINICAL_TRIALS trial_result · 2020-09-14Clinical Trial Update: Malaysia Stop Tyrosine Kinase Inhibitor Trial [Phase 3]
A Phase 3 clinical trial update from Malaysia regarding a Tyrosine Kinase Inhibitor for leukemia, chronic myeloid leukemia; current status i…
-
CLINICAL_TRIALS trial_result · 2020-09-01Clinical Trial Update: Study of Nilotinib as First Line Treatment in Philadelphia Chromosome Positive(Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) [Phase 2]
Phase 2 trial update on nilotinib as first-line treatment for Philadelphia chromosome–positive chronic myeloid leukemia in chronic phase.
-
CLINICAL_TRIALS trial_result · 2020-08-12Clinical Trial Update: IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT [Phase 1, Phase 2]
Clinical trial update on an IL-15 super agonist ALT-803 for relapse of hematologic malignancies after allogeneic stem cell transplant, compl…
-
FDA approval · 2020-08-10FDA Approved: GLEEVEC — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GLEEVEC (imatinib mesylate) from Novartis, approving changes to the product labeling based o…
-
CLINICAL_TRIALS trial_result · 2020-08-07Clinical Trial Update: Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW) [Phase 1, Phase 2]
Phase 1/2 trial evaluating combinations or sequential use of therapies with tyrosine kinase inhibitors in chronic phase chronic myeloid leuk…
-
FDA approval · 2020-07-23FDA Approved: IMATINIB MESYLATE — Original Application (BluePoint Laboratories)
FDA approved imatinib mesylate as an original-application generic drug for BluePoint Laboratories.
-
FDA approval · 2020-07-10FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for ICLUSIG (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc., approving changes t…
-
FDA label_change · 2020-06-17FDA Approved: BOSULIF — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved a supplemental application for BOSULIF (bosutinib) filed by Pfizer, resulting in updated labeling for the drug.
-
FDA approval · 2020-06-17FDA Approved: ICLUSIG — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Iclusig (ponatinib hydrochloride) from Takeda Pharmaceuticals America, Inc.
-
CLINICAL_TRIALS trial_result · 2020-04-13Clinical Trial Update: STI571 ProspectIve RandomIzed Trial: SPIRIT [Phase 3]
Phase 3 randomized trial update for STI571 (imatinib) in chronic myeloid leukemia has completed.